The US Federal Trade Commission (FTC) continued its push against deals that delay the entry of generic drugs, while it settled claims that Endo International PLC broke antitrust laws by entering into agreements with rivals to stave off competition to two of its top-selling medications.
The commission on Monday filed new complaints against Watson Laboratories Inc, its former parent Allergan PLC, and Impax Laboratories Inc over agreements that kept generic versions of Endo’s drugs off the market.
Endo made deals with the companies to delay the release of generic versions of two pain relievers — Lidoderm and Opana ER — to preserve monopoly profits, the commission alleged.
“Endo knew that generic competition would decimate its Lidoderm sales and that any delay in generic competition would be highly profitable for Endo, but very costly for consumers,” the commission said in a complaint filed in US federal court in San Francisco.
Endo settled those claims by agreeing not to enter into such deals. It did not admit wrongdoing or pay a penalty.
The settlement is “consistent with the company’s position that the Lidoderm and Opana ER settlements fully complied with the law both at the time they were executed and today,” Endo chief legal officer Matthew Maletta said.
The FTC voted two to one to file the complaint against Watson and Allergan, with commissioner Maureen Ohlhausen dissenting.
The vote marks at least the second time in a week that Ohlhausen has dissented in an enforcement action brought by her two fellow commissioners.
She opposed a complaint filed on Tuesday last week against Qualcomm Inc that accused the chipmaker of illegally maintaining a monopoly.
Teva Pharmaceutical Industries Ltd became the parent company of Watson in August last year after acquiring the unit from Allergan.
Representatives for Allergan and Teva declined to comment.
Representatives for Impax did not immediately respond to requests for comment.
Teva shares on Monday fell 1.6 percent to close at US$32.71, while Endo shares fell 1.4 percent to US$12.17. Allergan shares rose less than 1 percent to US$214.82.
The complaints against Watson, Allergan and Impax revive claims filed by the commission in March in federal court in Philadelphia.
The agency said that in 2012 Endo agreed to pay Watson, which was the first to seek regulatory approval for a generic Lidoderm patch, to hold off on entering the market for more than a year.
Endo’s payment to Watson was worth at least US$250 million, the commission said.
“Patients were denied the opportunity to purchase lower-cost generic versions of Lidoderm, forcing them and other purchasers to pay hundreds of millions of dollars more for this medication,” it said.
In the complaint against Impax, the commission said that Impax and Endo illegally agreed in 2010 that Impax would not compete by marketing a generic version of Endo’s Opana ER until January 2013.
In exchange, Endo paid Impax more than US$112 million, it said.
Lidoderm is a patch used to relieve pain related to shingles. Opana ER is an extended-release opioid.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last